MedPath

Merck Europe BV

🇳🇱Netherlands
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

59

CIMA_AEMPS:25
NMPA:15
EMA:11
+1 more agencies

Drug Approvals

Recombinant Human Choriogonadotropin alfa Solution for Injection

Product Name
艾泽
Approval Number
国药准字SJ20130091
Approval Date
Aug 2, 2023
NMPA

Recombinant Human Follitropin Alfa Solution for Injection

Product Name
果纳芬
Approval Number
国药准字SJ20235002
Approval Date
May 11, 2023
NMPA

Recombinant Human Follitropin for Injection

Product Name
果纳芬
Approval Number
国药准字SJ20181008
Approval Date
Jan 16, 2023
NMPA

Cetuximab Solution for Infusion

Product Name
爱必妥
Approval Number
国药准字SJ20171039
Approval Date
Oct 10, 2022
NMPA

Recombinant Human Lutropin alfa for Injection

Product Name
乐芮
Approval Number
国药准字SJ20181004
Approval Date
Oct 10, 2022
NMPA

Recombinant Human Lutropin alfa for Injection

Product Name
乐芮
Approval Number
国药准字SJ20181005
Approval Date
Oct 10, 2022
NMPA

Recombinant Human Follitropin Alfa Solution for Injection

Product Name
果纳芬
Approval Number
国药准字SJ20160041
Approval Date
Aug 27, 2021
NMPA

Recombinant Human Follitropin Alfa Solution for Injection

Product Name
果纳芬
Approval Number
国药准字SJ20160040
Approval Date
Aug 27, 2021
NMPA

Recombinant Human Follitropin Alfa Solution for Injection

Product Name
果纳芬
Approval Number
国药准字SJ20160039
Approval Date
Aug 27, 2021
NMPA

Recombinant Human Choriogonadotropin alfa Solution for Injection

Product Name
艾泽
Approval Number
S20130091
Approval Date
Mar 26, 2020
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.